FDA cites Sanofi for failures at French plant; BMS gets pricing pressure from California;

 @FiercePharma: FDA hears critics on risk-management programs. Article | Follow @FiercePharma

> Sanofi-Aventis (SASY.PA) failed to follow proper manufacturing procedures at a vaccine plant in France, U.S. regulators said in a letter released on Thursday. News

> California is pressuring Bristol-Myers Squibb to reduce the cost of a key AIDS medication, Reyataz, which carries an average wholesale price of $13,046 per year. Report

> U.S. health officials warned about the risk of pneumonia with Cubist Pharmaceuticals' (CBST.O) flagship antibiotic Cubicin. Article

> Celgene's (CELG) second-quarter earnings rose 8.8 percent, as sales growth continued for its flagship blood cancer drug Revlimid. Story

> Advisers have warned that companies could be open to probes from the taxman after European judges ruled AstraZeneca must account for VAT when passing on shopping vouchers to staff in salary sacrifice schemes. Report

> AstraZeneca appointed Dr. Bruce Burlington, a former official in the FDA's devices division, as a non-executive director with effect from August 1. Release

> Glenmark Generics launched its version of the McNeil Pediatrics drug Flexeril, used to treat muscle spasms. News

Biotech News

 @FierceBiotech: NEJM lays out questions--and facts--about Provenge. Report | Follow @FierceBiotech

 @JohnCFierce: Genzyme breaks the $70 barrier on this morning's stories. Article | Follow @JohnCFierce

> FDA lifts hold on Geron study. Item

> Orexigen weight-loss drug shows positive results in study. Report

> Molineaux turns her attention to start-up Calithera. News

> Anacor gets $15M from GSK. Story

And Finally... Stands to reason, but now there's proof that low serotonin can make you cry. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.